BLFS: Pangali Forward P/E BioLife Solutions, Inc.
The BioLife Solutions, Inc. (BLFS) strategy is based on pricing power achieved through FDA protocols. The company's forward P/E metric, provided by the GURU.Markets platform, visualizes the path toward this goal, while the value of 134.00 captures the metric level. Growth is constrained by costs associated with smart containers and cloud monitoring, as well as a dependence on stable demand for cryopreservation consumables.
Rincian metrik keuangan lan pasar BioLife (BLFS)
- nilai saham lan prakiraan konsensus rega:
- informasi kapitalisasi pasar:
- informasi kapitalisasi buku:
- rincian utang lan likuiditas:
Rasio Total Utang marang Ekuitas BioLife Solutions, Inc.|BLFS - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas BioLife Solutions, Inc.|BLFS - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku BioLife Solutions Inc|BLFS - Utang jangka dawa|Utang jangka cendhak perusahaan BioLife Solutions|Indikator likuiditas cepet biolifesolutions.com
- statistik bathi lan rasio pasar:
BLFS - Bathi resik|Bathi mangsa ngarep BioLife Solutions, Inc.|BLFS - Rasio rega pasar marang bathi resik|Pangali Forward P/E BioLife Corp|BLFS - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan BioLife Solutions Inc|BLFS - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan BioLife Solutions|BLFS - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan biolifesolutions.com|BLFS - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep BioLife Solutions, Inc.
Analisis dhasar perusahaan:BLFS BioLife Solutions
BioLife Solutions, Inc. (BLFS) revenues depend on the demand from biopharmaceutical centers for cryogenic equipment and specialized solutions. The company's forward P/E ratio correlates current market capitalization with expected annual earnings. Analyzing this metric allows for an assessment of the premium paid for future business growth. The trend in the company's forward P/E ratio reveals deviations of market value from fundamental expectations, helping investors determine the fairness of asset valuations.
Pesaing BioLife Solutions, Inc. (BLFS)
Rega marang bathi mangsa ngarep Tempus Labs (TEM)|Rega marang bathi mangsa ngarep QGEN (Qiagen NV)|Pangali Forward P/E IONS (Ionis Pharma)|Kapitalisasi marang proyeksi bathi Repligen Inc. (RGEN)|Avidity Biosciences - Pangali Forward P/E|Rasio rega marang bathi sing dikarepake CRSP|WGS: Pangali Forward P/E|Rasio prakiraan rega marang bathi Ultragenyx Pharmaceutical Inc. (RARE)|Prakiraan rega marang bathi BEAM|SRPT: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Twist Bioscience (TWST)|Kapitalisasi marang proyeksi bathi 10xgenomics.com|Rega marang bathi mangsa ngarep Intellia Therapeutics, Inc. NTLA|Stoke Therapeutics Inc (STOK) - Rasio prakiraan rega marang bathi|WVE - Rega marang bathi mangsa ngarep|MAZE: Rega marang bathi mangsa ngarep|SION (Sionna Therapeutics Inc) - Prakiraan rega marang bathi|primemedicine.com (PRME) - Pangali Forward P/E|Prakiraan rega marang bathi TSHA|QURE (uniQure NV) - Rasio kapitalisasi marang bathi mangsa ngarep|Pangali Forward P/E MGTX|Kapitalisasi marang proyeksi bathi REGENXBIO Corp|Rega marang bathi mangsa ngarep Solid Biosciences Inc. SLDB|ocugen.com (OCGN) - Rasio prakiraan rega marang bathi|PACB - Rega marang bathi mangsa ngarep|BNTC (Benitec Biopharma Inc) - Rasio rega marang bathi mangsa ngarep|Design Pharma (DSGN) - Rega marang bathi mangsa ngarep|RCKT - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi FDMT|LXEO: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E KRRO|Kapitalisasi marang proyeksi bathi Editas Medicine Inc|Rega marang bathi mangsa ngarep Silence Therapeutics Inc. SLN|PRQR: Rasio rega marang bathi mangsa ngarep|Codexis Bio - Pangali Forward P/E|sangamo.com (SGMO) - Prakiraan rega marang bathi|NAUT (nautilus.bio) - Prakiraan rega marang bathi|MGX - Kapitalisasi marang proyeksi bathi|DTIL (Precision BioSciences, Inc.) - Pangali Forward P/E|Rega marang bathi mangsa ngarep GBIO|Rega marang bathi mangsa ngarep Boundless Bio, Inc. (BOLD)|Rega marang bathi mangsa ngarep XCUR (exicuretx.com)|Pangali Forward P/E IMNN (Imunon)|PHIO (Phio Pharmaceuticals Corp) - Rasio rega marang bathi sing dikarepake|MBIO - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi TransCode Therapeutics RNAZ|BNGO: Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep APDN|Rega marang bathi mangsa ngarep bluebird bio|Rasio rega marang bathi mangsa ngarep IPA (ImmunoPrecise)|Pangali Forward P/E OMGA|Pangali Forward P/E Singular Genomics Corp (OMIC)|Pangali Forward P/E RGLS (Regulus Therapeutics)|syros.com - Rega marang bathi mangsa ngarep|Telesis Bio - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi TRACON Pharmaceuticals Inc. TCON|Unity Bio (UBX) - Rega marang bathi mangsa ngarep
